

## Special Issue

# Radionuclide Therapy and Hybrid Imaging in Oncology

### Message from the Guest Editors

This Special Issue addresses the role of radionuclides for diagnostic and therapeutic purposes in oncology. A variety of radionuclides have been introduced for hybrid imaging combining molecular imaging (i.e., single photon emission computed tomography (SPECT) or positron emission tomography (PET)) with data from morphological imaging (i.e., computer tomography (CT) and magnetic resonance imaging (MRI)). 18F-FDG PET/CT is the most frequently used form of hybrid imaging and has formed an integral part of diagnostic workup in oncology for several years.

---

### Guest Editors

Dr. Amir Sabet

Department of Nuclear Medicine, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany

Prof. Dr. Frank Grünwald

Department of Nuclear Medicine, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany

---

### Deadline for manuscript submissions

closed (29 February 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/91705](https://mdpi.com/si/91705)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)